Austin Biotech Firm Featured in New Podcast Episode
The BioMedWire podcast recently spotlighted Lucid-MS development and the unbuzzd IPO process.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies are successfully developing better treatments for chronic conditions?
Austin-based IBN has released a new episode of The BioMedWire Podcast featuring industry expert Anthony Durkacz. The discussion highlights progress on the Lucid-MS Phase 2 clinical trials and the upcoming IPO process for unbuzzd.
Why it matters
The featured developments mark a shift for Quantum BioPharma as it advances its multiple sclerosis treatment and manages its investment portfolio in unbuzzd. These updates offer insight into the company's financial structure and future commercial goals.
Quantum BioPharma holds an approximate 20% stake in unbuzzd, paired with a 7% royalty rate on sales until the $250 million threshold is reached. It remains unclear exactly when the IPO process will conclude or when the full marketing launch will begin.
The players
Anthony Durkacz
An industry expert who discussed clinical trials and IPO processes on the latest podcast episode.
Quantum BioPharma Ltd.
A company focused on developing therapies for multiple sclerosis and managing biotechnology investments.
IBN
An Austin-based firm that manages the syndication and production of industry podcasts.
The details
Quantum BioPharma is developing Lucid-MS to target myelin degradation in multiple sclerosis patients, with the therapy currently moving into Phase 2 trials. Additionally, the company is preparing for the commercial rollout of unbuzzd, following a peer-reviewed study published in March 2026. IBN serves over 500 companies through its syndication channels, delivering these updates as part of its ongoing industry reporting.
Timeline
March 2026: Peer-reviewed study on unbuzzd published.
June 30, 2026: Quantum BioPharma held a 19.48% stake in unbuzzd.
September 30, 2026: IBN released the new podcast episode.
The Texas Context
The clinical progression of Lucid-MS fits into the ongoing research trend of targeting myelin repair for multiple sclerosis patients. This milestone updates the company's status in the competitive biotechnology sector, following historical precedents for drug development cycles.
Local investors and industry watchers can track the progress of Quantum BioPharma as the company advances its Phase 2 clinical trials. Shareholders should monitor official filings for updates on the unbuzzd IPO timeline as the company moves toward a marketing launch.
The takeaway
The progression of Lucid-MS into Phase 2 trials signals a key developmental shift for local biotechnology efforts. Interested observers should monitor the IPO process for unbuzzd to see when the company pivots to its planned marketing launch.
Further reading
Keep up with the latest industry shifts at the Biotech section.
More information
To hear the full discussion on these clinical and financial developments, visit the BioMedWire podcast.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical companies are successfully developing better treatments for chronic conditions?
